Review
doi: 10.1186/1756-8722-2-22.
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer
Affiliations
- PMID: 19486511
- PMCID: PMC2695818
- DOI: 10.1186/1756-8722-2-22
Item in Clipboard
Review
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer
J Hematol Oncol.
.
Abstract
DNA methylation and histone acetylation are two well known epigenetic chromatin modifications. Epigenetic agents leading to DNA hypomethylation and histone hyperacetylation have been approved for treatment of hematological disorders. The first histone deacetylase inhibitor, vorinostat, has been licensed for cutaneous T cell lymphoma treatment. More than 11 new epigenetic agents are in various stages of clinical development for therapy of multiple cancer types. In this review we summarize novel histone deacetylase inhibitors and new regimens from clinical trials for epigenetic therapy of cancer.
Similar articles
-
Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.Anticancer Drugs. 2010 Oct;21(9):805-13. doi: 10.1097/CAD.0b013e32833dad91. Anticancer Drugs. 2010. PMID: 20679890 Review.
-
Targeting histone deacetylases: development of vorinostat for the treatment of cancer.Epigenomics. 2010 Jun;2(3):457-65. doi: 10.2217/epi.10.20. Epigenomics. 2010. PMID: 22121904 Review.
-
Epigenetic therapy of cancer with histone deacetylase inhibitors.J Cancer Res Ther. 2014 Jul-Sep;10(3):469-78. doi: 10.4103/0973-1482.137937. J Cancer Res Ther. 2014. PMID: 25313724 Review.
-
Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of CDKN1A.Clin Epigenetics. 2017 Jun 8;9:62. doi: 10.1186/s13148-017-0359-x. eCollection 2017. Clin Epigenetics. 2017. PMID: 28603560 Free PMC article.
-
Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.Curr Protein Pept Sci. 2018;19(3):333-340. doi: 10.2174/1389203718666170106101133. Curr Protein Pept Sci. 2018. PMID: 28059044 Review.
Cited by
-
Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.Curr Pharm Des. 2013;19(4):578-613. doi: 10.2174/138161213804581918. Curr Pharm Des. 2013. PMID: 23016851 Free PMC article. Review.
-
Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand.J Hematol Oncol. 2010 Jan 5;3:1. doi: 10.1186/1756-8722-3-1. J Hematol Oncol. 2010. PMID: 20051128 Free PMC article.
-
Suberoyl bishydroxamic acid inhibits the growth of A549 lung cancer cells via caspase-dependent apoptosis.Mol Cell Biochem. 2010 Nov;344(1-2):203-10. doi: 10.1007/s11010-010-0543-1. Epub 2010 Jul 22. Mol Cell Biochem. 2010. PMID: 20652372
-
Combination of Salermide and Cholera Toxin B Induce Apoptosis in MCF-7 but Not in MRC-5 Cell Lines.Int J Prev Med. 2013 Dec;4(12):1402-13. Int J Prev Med. 2013. PMID: 24498496 Free PMC article.
-
Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?J Biomed Biotechnol. 2011;2011:856985. doi: 10.1155/2011/856985. Epub 2010 Dec 6. J Biomed Biotechnol. 2011. PMID: 21188173 Free PMC article. Review.
References
-
- Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006;5:37–50. - PubMed
-
- Hashimshony T, Zhang J, Keshet I, Bustin M, Cedar H. The role of DNA methylation in setting up chromatin structure during development. Nature Genet. 2003;34:187–192. - PubMed
-
- Cang S, Liu DL. Clinical advances in hypomethylating agents for epigenetic therapy of cancer. Current Cancer Drug Targets submitted and under review. 2009. - PubMed
-
- Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene. 2007;26:1351–1356. - PubMed
-
- Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs. 2005;14:1497–1511. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
